Reference is made to the stock exchange announcement by Ultimovacs ASA (the
"Company") on 17 December 2024 regarding the agreement to combine its business
with Zelluna Immunotherapy AS (the "Business Combination") and the fully
committed private placement (the "Private Placement" and together with the
Business Combination, the "Transactions").


Please see the attached forms for information on the conditional allocation of
shares in the Company to closely related parties of primary insiders in
connection with the Transactions. The transactions reported by in the forms are
conditional upon approval by an extraordinary general meeting of the Company and
the subsequent completion of the Business Combination and the Private
Placement.


This information is subject to the disclosure requirements in article 19 of
Regulation EU 596/2014 (the "EU Market Abuse Regulation") and section 5-12 of
the Norwegian Securities Trading Act.

